Floatz logo

Fludarabine

Recurrent Mycosis Fungoides/Sezary Syndrome

National Cancer Institute (NCI)Small moleculePhase 2Active
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

50 Active assets in the Recurrent Mycosis Fungoides/Sezary Syndrome cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Virogen Biotechnology Inc.
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
FILGRASTIM
Mayo Clinic
Phase 4BBB
METHOTREXATE
Polish Lymphoma Research Group
Phase 4BBB
Inno-206
Pierluigi Porcu
Phase 4BBB

View all 50 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →